At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 60 enrolled
Drug / intervention
BIA 2-093drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate 400mg, 600mg and 800mg Tablets Clinical Trial Formulation (CTF) Versus the To-be-marketed Formulation (TBM) in Healthy Male and Female
In Brief
A Phase 1 clinical trial evaluating BIA 2-093 for Epilepsy. Completed, enrolled 60 participants.
Detailed Summary
Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover design
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
Primary CompletionJun 2007
First PostedNov 2014
TodayJul 2026
First PostedNov 5, 2014
Enrollment StartMay 1, 2007
Primary CompletionJun 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.7 years ago
Interventions
BIA 2-093drug